Want to join the conversation?
$LLY and AstraZeneca said they received U.S. Food and Drug Administration (FDA) Fast Track designation for development program in Alzheimer's disease for AZD3293, oral beta secretase cleaving enzyme (BACE) inhibitor now in phase 3 clinical trials. $LLY and AstraZeneca also announced planned initiation of second phase 3 trial for AZD3293.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.